Your panelist data lives in a spreadsheet. Your biophysical readings live in a proprietary instrument file. Your eTMF gets assembled the week before an inspection. And your safety team can't see a mild reaction pattern repeating across three concurrent studies — because those three studies live in three different systems.
Every handoff is a data integrity risk. Every re-entry is a compliance gap. Every new regulation adds another spreadsheet.
WHAT'S INSIDE
- The full 12-step clinical testing process — from protocol design through post-market cosmetovigilance — explained in plain terms
- A breakdown of the six-layer technology stack cosmetics testing runs on today (and where it breaks down)
- How MoCRA, EU Omnibus, and China NMPA reforms are reshaping compliance obligations in 2026
- A module-by-module map of how a unified eClinical platform closes the gaps between recruitment, EDC, eTMF, safety, and financials
- A side-by-side comparison: fragmented toolchain vs. unified platform, step by step
WHY IT MATTERS NOW
MoCRA introduced mandatory facility registration, product listing, and 15-day serious adverse event reporting — the first overhaul of US cosmetics law since 1938. The EU Omnibus updates hit a hard compliance deadline in May 2026. China's NMPA has opened new animal-testing-exempt pathways with their own documentation demands.
None of this is a temporary spike. It's the new baseline — and the fragmented toolchain most teams run on wasn't built for it.
